NCT01554254View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2013

Conditions
Cord Blood TransplantHematologic MalignancyInherited Metabolic Disease
Interventions
DRUG

TXA127

300mcg/kg/day, subcutaneous injection for up to 28 days

Trial Locations (1)

27710

Pediatric Bone and Cord Blood, Duke Univ. Med. Center, Durham

Sponsors
All Listed Sponsors
lead

Tarix Pharmaceuticals

INDUSTRY